A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes

Most antibody–drug conjugates (ADC) approved for the treatment of cancer contain protease-cleavable linkers. ADCs that traffic to lysosomes traverse highly acidic late endosomes, while ADCs that recycle to the plasma membrane traffic through mildly acidic sorting and recycling endosomes. Although en...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez Bay, Andres E., Faulkner, Devon, DaSilva, John O., Young, Tara M., Yang, Katie, Giurleo, Jason T., Ma, Dangshe, Delfino, Frank J., Olson, William C., Thurston, Gavin, Daly, Christopher, Andreev, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978886/
https://www.ncbi.nlm.nih.gov/pubmed/36861363
http://dx.doi.org/10.1158/1535-7163.MCT-22-0414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978886/
https://www.ncbi.nlm.nih.gov/pubmed/36861363
http://dx.doi.org/10.1158/1535-7163.MCT-22-0414

Ejemplares similares